JAMA Cardiology

@jamacardiology.com

359 Followers 20 Following

JAMA Cardiology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. šŸŒ JAMACardiology.com

Figure 1 from JAMA Cardiology shows atrial conduction pathways in a heart (A), detailing nodes & bundles. Panel B illustrates normal, partial, and advanced interatrial block, comparing atrial activation patterns with corresponding P-wave morphologies and durations (<0.10s, >0.12s).
Kaplan-Meier curves show 2-year all-cause mortality for AS patients with positive treadmill stress test. Panel A: overall mortality rises over 24 months. Panel B: stratified by stress test criteria, mortality is highest for symptoms, then SBP drop, lowest for arrhythmias (P=.64).
JAMA Cardiology RCT: Digital intervention significantly lowered LDL-C in 1465 adults (mean age 62.3y) with atherosclerotic cardiovascular disease. LDL-C at 6 months: Intervention ~77 mg/dL, Usual Care ~85 mg/dL. Adjusted diff: -6.62 mg/dL (P=.004).
Two bar graphs display concordance of estimated vs measured LDL-C. Graph A, from a reference lab (TG <400 mg/dL), compares Friedewald, Sampson-NIH, Martin-Hopkins, & MARS methods across LDL-C categories. Graph B, FOURIER, presents similar data for <20 & 20-39 mg/dL.
JAMA Cardiology editorial: 'Reigniting the Effort to Prevent Premature Death and Extend Healthy Life Span' by Robert M. Califf, MD, MACC. Published online July 15, 2026. DOI: 10.1001/jamacardio.2026.2446.
Twelve choropleth maps of the US show state-level percentages for various health risk factors (e.g., high blood pressure, cholesterol, BMI, kidney dysfunction) and environmental exposures (e.g., dietary risks, tobacco, lead, pollution), using diverse color gradients.
Webpage for JAMA Cardiology article: "Maternal Diabetes and Risk of Early-Onset Cardiovascular Diseases in Offspring" by Xingbo Mo, Imre Janszky, Hui Wang, et al. Published May 13, 2026. DOI: 10.1001/jamacardio.2026.0915.
Two bar graphs show Finerenone treatment effects on cardiovascular events based on baseline SBP (P=.96) and DBP (P=.83). Both graphs display a distribution of baseline blood pressure, with a generally stable treatment effect (around 1.1, marked by an orange line) across different pressure ranges.
JAMA Cardiology: 'Projected US Cardiovascular Disease Burden From Heat Exposure.' Figure 3 shows three bar charts. A: US population ages, with 65+ percentage rising from 2016 to 2095. B: DALY per 100,000 highest for age 65+. C: Total heat-attributable DALYs (life-years) are greater with demographic aging and higher GHG scenarios.
Bar graph: Responder Analyses of Categorical Change in Peak Oxygen Uptake (pVOā‚‚) with Aficamten vs Metoprolol at 24 Weeks. Metoprolol group shows higher rates of deterioration, while Aficamten shows higher rates of improvement across categories.
Two axial chest CT scans. A: Arterial phase (0 sec) shows the heart and lungs. B: Delayed phase (35 sec) reveals a darker pericardial effusion surrounding the heart, highlighted by multiple yellow arrowheads.
Two bar graphs show Finerenone treatment effects on cardiovascular events based on baseline SBP (P=.96) and DBP (P=.83). Both graphs display a distribution of baseline blood pressure, with a generally stable treatment effect (around 1.1, marked by an orange line) across different pressure ranges.
Line graph: Cardiac Frataxin (FXN) Levels Before & 3 Months Post AAVrh.10hFXN Therapy. Y-axis: FXN protein expression. X-axis: Patient treatment stage across 3 dose groups: 1.8x10^11, 5.6x10^11, 1.2x10^12 vg/kg. All patient lines show increased FXN levels. Average increases: 29%, 81% (92%), & 123% (74%) for the respective doses.
JAMA Cardiology article, "Original Investigation": "Resuscitation Quality Improvement Program for CPR Training and Cardiac Arrest Survival in Hospitals." Authors include Paul S. Chan, Steven M. Bradley, John A. Spertus, et al. Published May 20, 2026. DOI: 10.1001/jamacardio.2026.1074.
Two bar graphs show Finerenone treatment effects on cardiovascular events based on baseline SBP (P=.96) and DBP (P=.83). Both graphs display a distribution of baseline blood pressure, with a generally stable treatment effect (around 1.1, marked by an orange line) across different pressure ranges.
Two bar graphs show Finerenone treatment effects on cardiovascular events based on baseline SBP (P=.96) and DBP (P=.83). Both graphs display a distribution of baseline blood pressure, with a generally stable treatment effect (around 1.1, marked by an orange line) across different pressure ranges.
Line graph: Cardiac Frataxin (FXN) Levels Before & 3 Months Post AAVrh.10hFXN Therapy. Y-axis: FXN protein expression. X-axis: Patient treatment stage across 3 dose groups: 1.8x10^11, 5.6x10^11, 1.2x10^12 vg/kg. All patient lines show increased FXN levels. Average increases: 29%, 81% (92%), & 123% (74%) for the respective doses.
Two axial chest CT scans. A: Arterial phase (0 sec) shows the heart and lungs. B: Delayed phase (35 sec) reveals a darker pericardial effusion surrounding the heart, highlighted by multiple yellow arrowheads.
Bar graph: Responder Analyses of Categorical Change in Peak Oxygen Uptake (pVOā‚‚) with Aficamten vs Metoprolol at 24 Weeks. Metoprolol group shows higher rates of deterioration, while Aficamten shows higher rates of improvement across categories.
Table detailing PCSK9i utilization and spending in Medicare Part D, 2016-2023. It shows average spending per fill decreased after price reductions in 2019, while total beneficiaries, claims, and overall spending significantly increased for Alirocumab and Evolocumab.
Two medical scans. A: Cardiac magnetic resonance imaging, pretreatment, shows heart structures with yellow arrowheads. B: Cardiac computed tomography, posttreatment, highlights an area with asterisks. Both display internal cardiac anatomy.
Figure. Axial contrast-enhanced T1-weighted image reveals prominent homogeneous enhancement of the intrapericardial nodule (arrowhead) and massive pericardial effusion.
Climate change drives rising heat, increasing cardiovascular risk and DALYs, projected to triple by 2050, disproportionately affecting vulnerable populations (map shows US states). Health system responses: cooling infrastructure, urban canopy, occupational heat protection, decarbonization, & clinical risk assessment.
Two echocardiogram views of a heart. A: Commissural view shows the left atrium (LA), mitral valve (MV), and left ventricle (LV). The MV appears severely calcified. B: Short-axis view shows a cross-section of the mitral valve, also significantly calcified. Both scans show a heart rate of 96 bpm.
Bar graph: Responder Analyses of Categorical Change in Peak Oxygen Uptake (pVOā‚‚) with Aficamten vs Metoprolol at 24 Weeks. Metoprolol group shows higher rates of deterioration, while Aficamten shows higher rates of improvement across categories.
Line graph: Cardiac Frataxin (FXN) Levels Before & 3 Months Post AAVrh.10hFXN Therapy. Y-axis: FXN protein expression. X-axis: Patient treatment stage across 3 dose groups: 1.8x10^11, 5.6x10^11, 1.2x10^12 vg/kg. All patient lines show increased FXN levels. Average increases: 29%, 81% (92%), & 123% (74%) for the respective doses.
Two axial chest CT scans. A: Arterial phase (0 sec) shows the heart and lungs. B: Delayed phase (35 sec) reveals a darker pericardial effusion surrounding the heart, highlighted by multiple yellow arrowheads.
Table of key features from 15 randomized clinical trials for a meta-analysis. It lists each trial's name, year, HBR population sample size, Abbreviated and Comparator DAPT regimens, MCRB & HBR definitions, and follow-up period. Abbreviations are provided.
Two scatter plots compare hs-cTnT (fifth gen vs. sixth gen) measurements. Left shows correlation (ĻGen 5, Gen 6 = 0.98) up to 1250 ng/L, most points near y=x. Right zooms to 40 ng/L, revealing primary outcomes (0-gray, 1-red) where red points often exceed the y=x line.
Diagram: Optimizing P2Y12 inhibitor selection for PCI in ACS. It highlights an NMA of 15 RCTs on clopidogrel, prasugrel, and ticagrelor, notes prasugrel's superiority for MACE, MI, and ST, and emphasizes individualized assessment based on patient, lesion, and procedural features.
Figure 1: Four forest plots display Hazard Ratios (HRs) for Coronary Artery Disease based on lipoprotein(a) [Lp(a)] levels (>=125 nmol/L vs <125 nmol/L), stratified by quartiles of biomarkers: Interleukin 1beta, Interleukin 6, Interleukin 18, and NLR. Each plot shows HRs with 95% CIs & P-values, illustrating varying risk associations.
A JAMA Cardiology editorial: 'Toward a Lifetime Strategy for Aortic Valve Replacementā€”Ariadne's Thread' by Patrizio Lancellotti, Yun Yun Go, and Mani A. Vannan. Published Online: June 24, 2026. DOI: 10.1001/jamacardio.2026.0681.
Figure 2. Functional Impact and Location of RYR2-Glu336Gly. Panel A shows caffeine response graphs for RYR2-WT and RYR2-Glu336Gly, with the variant exhibiting delayed and higher calcium release. Panel B displays a 3D molecular structure, highlighting the Glu336Gly location.
Horizontal bar chart comparing 'Food supplementation winner' (blue), 'Usual care winner' (orange), & 'Ties' (light blue) across outcomes. Food supp. wins more in 'Overall' (43%) & 'KCCQ-CSS improvement' (30%). Usual care wins more for 'Total HF events' (17%). 'Ties' for KCCQ-CSS improvement are 21%. Win ratio: 1.21; 95% CI, 1.14-1.29; P<.001.
A JAMA Cardiology editorial on AI in Cardiology: "Interpreting AI-Enhanced ECG Performance in High-Risk, Resource-Limited Settings." By Fu Siong Ng, Anoop Shah, & Barbara Casadei. Published Online May 6, 2026. doi: 10.1001/jamacardio.2026.0709.
Figure 1. ROC curves for AI-ECG detection of LVSD & LVEF distribution. ROC shows high AUC (0.96-0.98) for FRS & CVD. Box plot shows LVEF by AI-ECG classification, with true positives & false negatives having lower LVEF values.
Bar graph: Responder Analyses of Categorical Change in Peak Oxygen Uptake (pVOā‚‚) with Aficamten vs Metoprolol at 24 Weeks. Metoprolol group shows higher rates of deterioration, while Aficamten shows higher rates of improvement across categories.
Two axial chest CT scans. A: Arterial phase (0 sec) shows the heart and lungs. B: Delayed phase (35 sec) reveals a darker pericardial effusion surrounding the heart, highlighted by multiple yellow arrowheads.
Line graph: Cardiac Frataxin (FXN) Levels Before & 3 Months Post AAVrh.10hFXN Therapy. Y-axis: FXN protein expression. X-axis: Patient treatment stage across 3 dose groups: 1.8x10^11, 5.6x10^11, 1.2x10^12 vg/kg. All patient lines show increased FXN levels. Average increases: 29%, 81% (92%), & 123% (74%) for the respective doses.
JAMA Cardiology Editor's Note: "Exploring Additional Cardiorenal Outcomesā€”Beyond the Primary Composite End Point" by Gregg C. Fonarow, MD, and John J. V. McMurray, MD. Published Online: March 28, 2026. DOI: 10.1001/jamacardio.2026.0780
Figure 2: Functional impact & 3D location of RYR2-Glu336Gly. Panel A graphs caffeine response, showing RYR2-Glu336Gly has higher peak Ca2+ release than RYR2-WT at lower concentrations. Panel B displays the 3D protein structure, highlighting the Glu336Gly variant's position.
JAMA Cardiology editorial titled "Prioritizing Time from Diagnosis to Quadruple Therapy in Heart Failure Care" by Neil M. Kalwani, Jessica R. Golbus, and Stephen J. Greene. Published online April 1, 2026. DOI: 10.1001/jamacardio.2026.0393.
Bar chart titled "Delays in Diagnosis Over Time." X-axis: Year (2016-2022); Y-axis: Patients, No. Legend: < 6 mo, 6 mo-< 1 y, ā‰„ 1 y. The number of patients with delays of ā‰„ 1 y increased significantly, peaking in 2021, while other delay categories remained lower.
Bar chart of 2021 mean 1-year costs ($) for hospitalization types: All cause, HF, CV, and Total cost. Costs are consistently highest for 'No GDMT', lower for 'Partial GDMT', and lowest for 'Optimal GDMT' across all types. E.g., Total cost for 'No GDMT' is ~$56K, 'Partial GDMT' ~$41K, 'Optimal GDMT' ~$32K.
Bar & line graph: TAVI procedures (2013-2022) by sex. Bars show proportion, %: Men consistently higher than women. Lines show total procedures: both sexes increase, men significantly more, from ~5k to ~30k, women ~5k to ~20k.
JAMA Cardiology RCT on Menaquinone-7 for coronary artery calcification. 150 participants (97M, 70W, avg 60y) with coronary artery disease. MK-7 significantly slowed calcium score increase by ~19 AU/year vs. placebo over 2 years (P=.02). A line graph shows the MK-7 group's CAC score increasing slower.
Figure 3: MRI and [68Ga]FAPI-46 PET/MRI scans of 4 patients with nonischemic cardiomyopathy. Top row shows gray MRI images; bottom row shows PET/MRI with colored overlays indicating SUVmax from 0.16 to 2.10.
A graph showing Probability of event vs. Time, d. A line indicates 'Achieved quadruple therapy,' steadily increasing from 0 to about 0.27 at 1750 days. Bar segments represent 'Death,' cumulatively increasing from 0 to approximately 0.38 at 1750 days.
Bar & line graph: TAVI procedures (2013-2022) by sex. Bars show proportion, %: Men consistently higher than women. Lines show total procedures: both sexes increase, men significantly more, from ~5k to ~30k, women ~5k to ~20k.
JAMA Cardiology editorial: "Coronary Artery Calcium Progressionā€”A Useful Outcome in Clinical Trials?" by Michael J. Blaha and Sungwoo Choi. Published online June 10, 2026. DOI: 10.1001/jamacardio.2026.1267.
Stacked bar charts show CKM stage changes over 3 years for Finerenone vs. Placebo. For baseline CKM stage 2, both groups show increasing progression to higher stages, with placebo slightly worse. For baseline CKM stage 3, Finerenone shows more improvement & less progression.
JAMA Cardiology Brief Report: "Multiple Endotypes and Angina Burden in Patients With Nonobstructive Coronary Arteries." Bar graph showing SAQ domain scores (Summary, Physical limitation, Angina stability, Angina frequency, Treatment satisfaction, Quality of life) across 0-3 endotypes.
JAMA Cardiology: Projected US Cardiovascular Disease Burden from Heat Exposure for Future Greenhouse Gas Scenarios. Figure 3 shows charts forecasting increased heat-attributable cardiovascular disease burden, especially for the aging US population (65+ age group), under various climate scenarios.
Figure 2: Functional impact & 3D location of RYR2-Glu336Gly. Panel A graphs caffeine response, showing RYR2-Glu336Gly has higher peak Ca2+ release than RYR2-WT at lower concentrations. Panel B displays the 3D protein structure, highlighting the Glu336Gly variant's position.
Kaplan-Meier plot shows cumulative incidence of venous thromboembolism. The Bempedoic acid curve (dark blue) indicates a lower incidence than the Placebo curve (orange) over 54 months. HR 0.58; 95% CI 0.39-0.86; P = .006. Numbers at risk are provided below the graph.
JAMA Cardiology Brief Report: "Multiple Endotypes and Angina Burden in Patients With Nonobstructive Coronary Arteries." Bar graph showing SAQ domain scores (Summary, Physical limitation, Angina stability, Angina frequency, Treatment satisfaction, Quality of life) across 0-3 endotypes.
JAMA study: Low-dose rivaroxaban did not reduce cardiovascular events in advanced CKD patients (22.6% vs 20.7% placebo, HR 1.09) but increased major bleeding (8.8% vs 6.0%). 1458 patients (1026M, 432F) mean age 63.
JAMA Cardiology: Projected US Cardiovascular Disease Burden from Heat Exposure for Future Greenhouse Gas Scenarios. Figure 3 shows charts forecasting increased heat-attributable cardiovascular disease burden, especially for the aging US population (65+ age group), under various climate scenarios.
Two bar charts show SUCRA values for drug efficacy & safety. Efficacy (MACE, MI, Stent thrombosis) shows Prasugrel highest (90-100%), then Ticagrelor (30-50%), then Clopidogrel (10-20%). Safety (Bleeding, ICH, Discontinuation) shows Clopidogrel highest (70-80%), then Prasugrel (45-60%), then Ticagrelor (5-20%).